What we do Sanjivani Paranteral Limited is a WHO-GMP certified pharmaceutical company specializing in manufacturing injectables and oral solids focused on life-saving drugs with exports to 25+ countries. |
Founded in 1,994 |
Market share Established leader with 25+ years experience, preferred partner for top pharma companies and growing nutraceutical presence in Europe. |
Problem solved Provides essential injectable and oral medications addressing critical healthcare needs in infections, chronic illnesses, and post-operative care. |
Top clients or who we serve Serves pharmaceutical companies like Ranbaxy, Lupin, Merind, and USV; B2B customers globally across Asia, Europe, Latin America, and India. |
Key management Chairman & MD Ashwani Khemka; Executive Director Srivardhan Ashwani Khemka; CFO Pritesh Jain; Independent Directors Monika Singhania, Abhay Shah. |
Our journey and innovations Founded in 1994, expanded via acquisition of Uttarakhand plant in 2009, launched strategic JV in Czech Republic for nutraceuticals in 2023, and new Pune IV fluids plant. |
Where we operate Manufacturing in India (Mumbai, Dehradun, Pune) and Czech Republic; exports to over 25 countries including Middle East, Africa, Latin America, CIS, and Europe. |
Top products or what we offer High-quality injectables, oral solids like tablets and capsules, and nutraceuticals including antibiotics, CNS, CVS, anti-diabetics, and anti-allergic drugs. |
Top brands Injectables and oral solids with ~160 formulations; JV brand Alevia Healthcare for nutraceuticals in Europe; SPL Infusion for IV fluids. |
Raw materials needed Active pharmaceutical ingredients (APIs), sterile vials, ampoules, powders, and liquid solvents for pharma formulations. |
Raw materials supplier Sourced from various global and local pharma raw material suppliers ensuring WHO-GMP compliance. |
Recurring vs cyclical contribution Revenue mix is largely recurring from ongoing pharmaceutical contract manufacturing and nutraceutical supply agreements. |
Our industry position Key player in Indian injectable pharma; expanding foothold in European nutraceuticals; partner to leading pharma firms; export-driven business model. |
Financial highlights FY25 revenue Rs. 70.1 Cr with PAT Rs. 8.09 Cr; Q3 FY26 revenue INR 208.6 Mn (up 20.3% YoY); PAT INR 26.2 Mn (up 37.8% YoY). |
Geographical revenue split Approximately 75% exports mainly to Middle East, Africa, Latin America, CIS countries; 25% domestic Indian revenue. |
Order book - |
Whats driving growth Portfolio expansion, geographic diversification, new product launches, strategic partnerships, and entry into the European nutraceutical market. |
Our future plans Scaling up in newer geographies, expanding product lines, boosting manufacturing capacity in India and Czech JV, and strengthening R&D efforts. |
Our green promise - |
Our people and values Committed to diversity with women directors; employee welfare programs; transparent corporate governance and ethical business practices. |
Key challenges ahead Navigating regulatory changes, competitive pressures, raw material costs, and maintaining quality across expanded operations. |
Interesting facts Among India's pioneers in injectable pharma; over 160 product formulations; strong presence in nutraceuticals via Czech JV. |
Risks and strategy Focus on compliance, diversification of product and market base, continuous innovation, and robust internal controls to mitigate risks. |
